Full Text of SB0030 95th General Assembly
SB0030sam001 95TH GENERAL ASSEMBLY
|
Sen. David Luechtefeld
Filed: 3/8/2007
|
|
09500SB0030sam001 |
|
LRB095 04252 RLC 33060 a |
|
| 1 |
| AMENDMENT TO SENATE BILL 30
| 2 |
| AMENDMENT NO. ______. Amend Senate Bill 30 by replacing | 3 |
| everything after the enacting clause with the following:
| 4 |
| "Section 5. The Illinois Controlled Substances Act is | 5 |
| amended by changing Sections 316, 317, 318, 319, and 320 and by | 6 |
| adding Section 321 as follows:
| 7 |
| (720 ILCS 570/316)
| 8 |
| Sec. 316. Schedule II controlled substance prescription | 9 |
| monitoring program.
| 10 |
| The Department must provide for a Schedule II controlled | 11 |
| substance
prescription monitoring program that includes the | 12 |
| following components:
| 13 |
| (1) The
Each time a Schedule II controlled substance is
| 14 |
| dispensed, the
dispenser must transmit to the
central | 15 |
| repository the following information:
| 16 |
| (A) The recipient's name.
|
|
|
|
09500SB0030sam001 |
- 2 - |
LRB095 04252 RLC 33060 a |
|
| 1 |
| (B) The recipient's address.
| 2 |
| (C) The national drug code number of the Schedule | 3 |
| II controlled
substance
dispensed.
| 4 |
| (D) The date the Schedule II controlled substance | 5 |
| is dispensed.
| 6 |
| (E) The quantity of the Schedule II controlled | 7 |
| substance dispensed.
| 8 |
| (F) The dispenser's United States Drug Enforcement | 9 |
| Administration
Agency
registration number.
| 10 |
| (G) The prescriber's United States Drug | 11 |
| Enforcement Administration
Agency
registration number.
| 12 |
| (2) The information required to be transmitted under | 13 |
| this Section must be
transmitted not more than 7
15 days | 14 |
| after the date on which a
Schedule II controlled substance | 15 |
| is dispensed.
| 16 |
| (3) A dispenser must transmit the information required | 17 |
| under this Section
by:
| 18 |
| (A) an electronic device compatible with the | 19 |
| receiving device of the
central repository;
| 20 |
| (B) a computer diskette;
| 21 |
| (C) a magnetic tape; or
| 22 |
| (D) a pharmacy universal claim form or Pharmacy | 23 |
| Inventory Control form;
| 24 |
| that meets specifications prescribed by the Department.
| 25 |
| Controlled
Schedule II controlled substance prescription | 26 |
| monitoring does not apply to
Schedule II controlled substance |
|
|
|
09500SB0030sam001 |
- 3 - |
LRB095 04252 RLC 33060 a |
|
| 1 |
| prescriptions as exempted under Section
313.
| 2 |
| (Source: P.A. 91-576, eff. 4-1-00; 91-714, eff. 6-2-00.)
| 3 |
| (720 ILCS 570/317)
| 4 |
| Sec. 317. Central repository for collection of | 5 |
| information.
| 6 |
| (a) The Department must designate a central repository for
| 7 |
| the collection of information transmitted under Section 316 and | 8 |
| 321 .
| 9 |
| (b) The central repository must do the following:
| 10 |
| (1) Create a database for information required to be | 11 |
| transmitted under
Section 316 in the form required under | 12 |
| rules adopted by the
Department, including search | 13 |
| capability for the following:
| 14 |
| (A) A recipient's name.
| 15 |
| (B) A recipient's address.
| 16 |
| (C) The national drug code number of a controlled | 17 |
| substance
dispensed.
| 18 |
| (D) The dates a Schedule II controlled substance is | 19 |
| dispensed.
| 20 |
| (E) The quantities of a Schedule II controlled | 21 |
| substance dispensed.
| 22 |
| (F) A dispenser's United States Drug Enforcement | 23 |
| Administration
Agency
registration number.
| 24 |
| (G) A prescriber's United States Drug Enforcement | 25 |
| Administration
Agency
registration number.
|
|
|
|
09500SB0030sam001 |
- 4 - |
LRB095 04252 RLC 33060 a |
|
| 1 |
| (2) Provide the Department with a
continuing 24
hour a | 2 |
| day on-line access to the database maintained by the | 3 |
| central
repository. The Department of Financial and
| 4 |
| Professional
Regulation must provide the
Department with | 5 |
| electronic access to the license information of a | 6 |
| prescriber or
dispenser. The Department of Financial and
| 7 |
| Professional Regulation may charge a fee for this
access | 8 |
| not to exceed the actual cost of furnishing the | 9 |
| information.
| 10 |
| (3) Secure the information collected by the central | 11 |
| repository and the
database maintained by the central | 12 |
| repository against access by unauthorized
persons. | 13 |
| No fee shall be charged for access by a prescriber or | 14 |
| dispenser.
| 15 |
| (Source: P.A. 91-576, eff. 4-1-00.)
| 16 |
| (720 ILCS 570/318)
| 17 |
| Sec. 318. Confidentiality of information.
| 18 |
| (a) Information received by the central repository under | 19 |
| Section 316 and 321
is confidential.
| 20 |
| (b) The Department must carry out a program to protect the
| 21 |
| confidentiality of the information described in subsection | 22 |
| (a). The Department
may
disclose the information to another | 23 |
| person only under
subsection (c), (d), or (f) and may charge a | 24 |
| fee not to exceed the actual cost
of
furnishing the
| 25 |
| information.
|
|
|
|
09500SB0030sam001 |
- 5 - |
LRB095 04252 RLC 33060 a |
|
| 1 |
| (c) The Department may disclose confidential information | 2 |
| described
in subsection (a) to any person who is engaged in | 3 |
| receiving, processing, or
storing the information.
| 4 |
| (d) The Department may release confidential information | 5 |
| described
in subsection (a) to the following persons:
| 6 |
| (1) A governing body
that licenses practitioners and is | 7 |
| engaged in an investigation, an
adjudication,
or a | 8 |
| prosecution of a violation under any State or federal law | 9 |
| that involves a
controlled substance.
| 10 |
| (2) An investigator for the Consumer Protection | 11 |
| Division of the office of
the Attorney General, a | 12 |
| prosecuting attorney, the Attorney General, a deputy
| 13 |
| Attorney General, or an investigator from the office of the | 14 |
| Attorney General,
who is engaged in any of the following | 15 |
| activities involving controlled
substances:
| 16 |
| (A) an investigation;
| 17 |
| (B) an adjudication; or
| 18 |
| (C) a prosecution
of a violation under any State or | 19 |
| federal law that involves a controlled
substance.
| 20 |
| (3) A law enforcement officer who is:
| 21 |
| (A) authorized by the Department of State Police to | 22 |
| receive
information
of the type requested for the | 23 |
| purpose of investigations involving controlled
| 24 |
| substances;
| 25 |
| (B) approved by the Department to receive | 26 |
| information of the
type requested for the purpose of |
|
|
|
09500SB0030sam001 |
- 6 - |
LRB095 04252 RLC 33060 a |
|
| 1 |
| investigations involving controlled
substances; and
| 2 |
| (C) engaged in the investigation or prosecution of | 3 |
| a violation
under
any State or federal law that | 4 |
| involves a controlled substance.
| 5 |
| (e) Before the Department releases confidential | 6 |
| information under
subsection (d), the applicant must | 7 |
| demonstrate in writing to the Department that:
| 8 |
| (1) the applicant has reason to believe that a | 9 |
| violation under any
State or
federal law that involves a | 10 |
| Schedule II controlled substance has occurred; and
| 11 |
| (2) the requested information is reasonably related to | 12 |
| the investigation,
adjudication, or prosecution of the | 13 |
| violation described in subdivision (1).
| 14 |
| (f) The Department may release to:
| 15 |
| (1) a governing
body that licenses practitioners;
| 16 |
| (2) an investigator for the Consumer Protection | 17 |
| Division of the office of
the Attorney General, a | 18 |
| prosecuting attorney, the Attorney General, a deputy
| 19 |
| Attorney General, or an investigator from the office of the | 20 |
| Attorney General;
or
| 21 |
| (3) a law enforcement officer who is:
| 22 |
| (A) authorized by the Department of State Police to | 23 |
| receive the type of
information released; and
| 24 |
| (B) approved by the Department to receive the type | 25 |
| of
information released; or
| 26 |
| (4) prescription monitoring entities in other states |
|
|
|
09500SB0030sam001 |
- 7 - |
LRB095 04252 RLC 33060 a |
|
| 1 |
| per the provisions outlined in subsection (g) and (h) | 2 |
| below;
| 3 |
| confidential prescription record information collected under | 4 |
| Sections 316 and 321
generated from computer records that | 5 |
| identifies vendors or
practitioners , or both, who are | 6 |
| prescribing or dispensing large quantities of a
Schedule II , | 7 |
| III, IV, or V controlled
substances outside the scope of their | 8 |
| practice, pharmacy, or business,
substance as determined by the | 9 |
| Advisory Committee created by Section 320.
| 10 |
| (g) The information described in subsection (f) may not be | 11 |
| released until it
has been reviewed by an employee of the | 12 |
| Department who is licensed as a
prescriber or a dispenser
and | 13 |
| until that employee has certified
that further investigation is | 14 |
| warranted. However, failure to comply with this
subsection (g) | 15 |
| does not invalidate the use of any evidence that is otherwise
| 16 |
| admissible in a proceeding described in subsection (h).
| 17 |
| (h) An investigator or a law enforcement officer receiving | 18 |
| confidential
information under subsection (c), (d), or (f) may | 19 |
| disclose the information to a
law enforcement officer or an | 20 |
| attorney for the office of the Attorney General
for use as | 21 |
| evidence in the following:
| 22 |
| (1) A proceeding under any State or federal law that | 23 |
| involves a
Schedule II controlled substance.
| 24 |
| (2) A criminal proceeding or a proceeding in juvenile | 25 |
| court that involves
a Schedule II controlled substance.
| 26 |
| (i) The Department may compile statistical reports from the
|
|
|
|
09500SB0030sam001 |
- 8 - |
LRB095 04252 RLC 33060 a |
|
| 1 |
| information described in subsection (a). The reports must not | 2 |
| include
information that identifies , by name, license or | 3 |
| address, any practitioner, dispenser, ultimate user, or other | 4 |
| person
administering a controlled substance.
| 5 |
| (j) Based upon Federal, initial and maintenance funding, a | 6 |
| prescriber and dispenser inquiry system shall be developed to | 7 |
| assist the medical community in its goal of effective clinical | 8 |
| practice and to prevent patients from diverting or abusing | 9 |
| medications.
| 10 |
| (1) An inquirer shall have read only access to a | 11 |
| stand-alone database which shall contain records for the | 12 |
| previous 6 months. | 13 |
| (2) Dispensers may, upon positive and secure | 14 |
| identification, make an inquiry on a patient or customer | 15 |
| solely for a medical purpose as delineated within the | 16 |
| Federal HIPAA law. | 17 |
| (3) The Department shall provide a one-to-one secure | 18 |
| link and encrypted software necessary to establish the link | 19 |
| between an inquirer and the Department. Technical | 20 |
| assistance shall also be provided. | 21 |
| (4) Written inquiries are acceptable but must include | 22 |
| the fee and the requestor's Drug Enforcement | 23 |
| Administration license number and submitted upon the | 24 |
| requestor's business stationary. | 25 |
| (5) No data shall be stored in the database beyond 24 | 26 |
| months. |
|
|
|
09500SB0030sam001 |
- 9 - |
LRB095 04252 RLC 33060 a |
|
| 1 |
| (6) Tracking analysis shall be established and used per | 2 |
| administrative rule. | 3 |
| (7) Nothing in this Act or Illinois law shall be | 4 |
| construed to require a prescriber or dispenser to make use | 5 |
| of this inquiry system.
| 6 |
| (8) If there is an adverse outcome because of a | 7 |
| prescriber making an inquiry, which is initiated in good | 8 |
| faith, the prescriber shall be held harmless from any civil | 9 |
| liability.
| 10 |
| (Source: P.A. 91-576, eff. 4-1-00.)
| 11 |
| (720 ILCS 570/319)
| 12 |
| Sec. 319. Rules. The Department must adopt rules under the | 13 |
| Illinois
Administrative
Procedure Act to
implement Sections | 14 |
| 316 through 321
318 , including the following:
| 15 |
| (1) Information collection and retrieval procedures | 16 |
| for the central
repository, including the Schedule II
| 17 |
| controlled substances to be included in
the program
| 18 |
| required under Section 316 and 321 .
| 19 |
| (2) Design for the creation of the database required | 20 |
| under Section
317.
| 21 |
| (3) Requirements for the development and installation | 22 |
| of on-line
electronic access by the Department to | 23 |
| information collected by the
central repository.
| 24 |
| (Source: P.A. 91-576, eff. 4-1-00.)
|
|
|
|
09500SB0030sam001 |
- 10 - |
LRB095 04252 RLC 33060 a |
|
| 1 |
| (720 ILCS 570/320)
| 2 |
| Sec. 320. Advisory committee.
| 3 |
| (a) The Secretary of Human Services must appoint an | 4 |
| advisory committee to
assist the Department in implementing the | 5 |
| Schedule II controlled substance
prescription
monitoring | 6 |
| program created by Section 316 and 321 of this Act.
The | 7 |
| Advisory Committee consists of prescribers and dispensers.
| 8 |
| (b) The Secretary of Human Services must determine the | 9 |
| number of members to
serve on the advisory committee. The | 10 |
| Secretary must choose one of the members
of the advisory | 11 |
| committee to serve as chair of the committee.
| 12 |
| (c) The advisory committee may appoint its other officers | 13 |
| as it deems
appropriate.
| 14 |
| (d) The members of the advisory committee shall receive no | 15 |
| compensation for
their services as members of the advisory | 16 |
| committee but may be reimbursed for
their actual expenses | 17 |
| incurred in serving on the advisory committee.
| 18 |
| (Source: P.A. 91-576, eff. 4-1-00.)
| 19 |
| (720 ILCS 570/321 new)
| 20 |
| Sec. 321. Schedule III, IV, and V controlled substance | 21 |
| prescription monitoring program. | 22 |
| (a) The Department shall provide for a Schedule III, IV, | 23 |
| and V controlled substances prescription monitoring program | 24 |
| contingent upon full funding from the authorized Federal agency | 25 |
| less incidental expenses. |
|
|
|
09500SB0030sam001 |
- 11 - |
LRB095 04252 RLC 33060 a |
|
| 1 |
| (b) Prescription data collected for Schedules III, IV, and | 2 |
| V shall include the components listed in Section 316(1), (2), | 3 |
| and (3). | 4 |
| (c) The information required to be transmitted under this | 5 |
| Section must be transmitted not more than 7 days after the date | 6 |
| on which a controlled substance is dispensed. | 7 |
| (d) If Federal funding is not provided, the Department | 8 |
| shall cease data collection for Schedules III, IV, and V. | 9 |
| (e) All requirements for this Section shall comply with the | 10 |
| federal HIPAA statute. ".
|
|